Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Mirum Pharmaceuticals, Inc. (MIRM) had Cost of Goods Sold of $81.64M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$336.89M |
|
$-87.94M |
|
|
Cost of Goods Sold |
$81.64M |
$255.25M |
|
$424.49M |
|
$-87.61M |
|
$0.69M |
|
$-86.91M |
|
$-86.91M |
|
$-87.94M |
|
$-87.94M |
|
$-87.94M |
|
$-87.94M |
|
$-87.61M |
|
$-62.32M |
|
47.52M |
|
47.52M |
|
$-1.85 |
|
$-1.85 |
|
| Balance Sheet Financials | |
$392.79M |
|
$1.14M |
|
$277.97M |
|
$670.75M |
|
$126.55M |
|
$308.08M |
|
$318.56M |
|
$445.11M |
|
$225.64M |
|
$-24.18M |
|
$225.64M |
|
48.34M |
|
| Cash Flow Statement Financials | |
$10.32M |
|
$-90.12M |
|
$17.70M |
|
$286.33M |
|
$222.93M |
|
$-63.40M |
|
$48.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.10 |
|
-- |
|
-- |
|
0.58 |
|
1.37 |
|
75.77% |
|
-26.00% |
|
-26.00% |
|
-18.50% |
|
-25.80% |
|
-26.10% |
|
$9.33M |
|
-- |
|
-- |
|
-- |
|
0.50 |
|
3.64 |
|
4.30 |
|
84.82 |
|
-38.97% |
|
363.71% |
|
-13.11% |
|
-16.48% |
|
$4.67 |
|
$0.20 |
|
$0.22 |
|